Leerink Partnrs Issues Optimistic Estimate for BNTC Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC) – Research analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for Benitec Biopharma in a report released on Wednesday, May 14th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will earn ($1.18) per share for the year, up from their previous forecast of ($1.22). The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2025 earnings at ($0.26) EPS and FY2026 earnings at ($1.05) EPS.

Several other analysts have also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Benitec Biopharma in a report on Monday. JMP Securities reissued a “market outperform” rating and set a $20.00 target price on shares of Benitec Biopharma in a research note on Thursday, May 15th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $24.71.

Benitec Biopharma Price Performance

NASDAQ:BNTC opened at $13.93 on Monday. The stock has a market cap of $356.61 million, a PE ratio of -9.23 and a beta of 0.34. Benitec Biopharma has a fifty-two week low of $5.74 and a fifty-two week high of $16.90. The stock’s 50-day moving average is $13.65 and its two-hundred day moving average is $12.07.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.12.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L acquired 900,000 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the acquisition, the director now owns 8,793,245 shares in the company, valued at approximately $114,312,185. The trade was a 11.40% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its holdings in Benitec Biopharma by 269.0% during the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company’s stock valued at $37,123,000 after purchasing an additional 2,142,643 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Benitec Biopharma by 198.5% in the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company’s stock worth $33,268,000 after buying an additional 1,739,904 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Benitec Biopharma by 134.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company’s stock worth $24,913,000 after buying an additional 1,131,129 shares during the period. Infinitum Asset Management LLC grew its stake in Benitec Biopharma by 435.7% in the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock valued at $14,636,000 after buying an additional 915,000 shares during the last quarter. Finally, Suvretta Capital Management LLC raised its holdings in Benitec Biopharma by 1.5% in the 4th quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company’s stock worth $113,165,000 after acquiring an additional 130,956 shares during the period. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.